Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$113.69 USD
-1.29 (-1.12%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
08/01/2024
Time: BMO |
6/2024 | $-1.27 | 2.78% |
Earnings Summary
For their last quarter, Blueprint Medicines (BPMC) reported earnings of -$1.32 per share, beating the Zacks Consensus Estimate of $-1.64 per share. This reflects a positive earnings surprise of 19.51%. Look out for BPMC's next earnings release on August 01, 2024. For the next earning release, we expect the company to report earnings of -$1.27 per share, reflecting a year-over-year increase of 42.01%.
Earnings History
Price & Consensus
Zacks News for BPMC
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services